Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

NCT04054882 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

702

Enrollment

INDUSTRY

Sponsor class

Conditions

Vaccination

Interventions

BIOLOGICAL: Sabin-IPV and DTaP
BIOLOGICAL: Sabin-IPV
BIOLOGICAL: DTaP

Sponsor

China National Biotec Group Company Limited

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]